Compare · ABT vs TRAX
ABT vs TRAX
Side-by-side comparison of Abbott Laboratories (ABT) and First Tracks Biotherapeutics Inc. (TRAX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABT and TRAX operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABT is the larger of the two at $181.14B, about 140.7x TRAX ($1.29B).
- Over the past year, ABT is down 19.0% and TRAX is up 85.6% - TRAX leads by 104.6 points.
- ABT has been more active in the news (11 items in the past 4 weeks vs 6 for TRAX).
- ABT has more recent analyst coverage (25 ratings vs 12 for TRAX).
- Company
- Abbott Laboratories
- First Tracks Biotherapeutics Inc.
- Price
- $104.88+0.16%
- $34.48-4.29%
- Market cap
- $181.14B
- $1.29B
- 1M return
- +2.58%
- -11.93%
- 1Y return
- -19.02%
- +85.58%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 11
- 6
- Recent ratings
- 25
- 12
Abbott Laboratories
Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. The Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and measure infectious agents; point of care systems; cartridges for testing blood; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The Nutritional Products segment provides pediatric and adult nutritional products. The Medical Devices segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; and diabetes care products, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded in 1888 and is based in North Chicago, Illinois.
Latest ABT
- Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop
- Barclays initiated coverage on Abbott Labs with a new price target
- Abbott receives FDA approval for new CardioMEMS HF System capabilities that help patients engage in the care of their heart condition
- SEC Form 4 filed by Director Stratton John G
- SEC Form 4 filed by Director Gonzalez Patricia Paola
- SEC Form 4 filed by Director Conroy Kevin T
- SEC Form 4 filed by Director Ahuja Nita
- SEC Form 4 filed by Director Roman Michael F
- Abbott Labs upgraded by Rothschild & Co Redburn with a new price target
- Abbott hosts conference call for third-quarter earnings
Latest TRAX
- SEC Form 8-K filed by First Tracks Biotherapeutics Inc.
- First Tracks Biotherapeutics Announces $200 Million Private Placement
- SEC Form 8-K filed by First Tracks Biotherapeutics Inc.
- First Tracks Biotherapeutics Announces Positive Top-Line Results for ANB033 in Gluten-Challenge Study in Celiac Disease
- First Tracks Biotherapeutics to Announce Top-Line Data from Cohort 1 of Phase 1b Trial of ANB033, a CD122 antagonist, in Celiac Disease on Oct. 12, 2026
- Canaccord Genuity initiated coverage on First Tracks Biotherapeutics with a new price target
- Evercore ISI initiated coverage on First Tracks Biotherapeutics with a new price target
- Director Orwin John A converted options into 1,300 shares, increasing direct ownership by 8% to 17,995 units (SEC Form 4)
- Guggenheim initiated coverage on First Tracks Biotherapeutics with a new price target
- SEC Form 144 filed by First Tracks Biotherapeutics Inc.